Accordingly, these data are insufficient to infer broad IGF-axis remodeling or altered IGF-II bioavailability, but they do motivate more rigorous, assay-validated studies to determine whether IGFBP-6 changes reproducibly in defined HCC contexts. This evidence concerns the gene IGF1 and hepatocellular carcinoma.